Journal
NEUROPSYCHOPHARMACOLOGY
Volume 39, Issue 10, Pages 2299-2308Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2014.88
Keywords
-
Categories
Funding
- Spanish Ministry of Health (ISCIII) [PI10/00297]
- Lottery Health Board of New Zealand (Ministry of Internal Affairs)
- Department of Psychology, University of Canterbury, New Zealand
- Fondazione Compagnia di San Paolo (Torino, Italy)
- F Hoffman-La Roche
Ask authors/readers for more resources
The trace amine-associated receptor 1 (TAR1) has emerged as a promising target for medication development in addiction because of its ability to regulate dopamine (DA) transmission. We tested in rats the efficacy of RO5203648 and RO5256390, partial and full TAAR1 agonists, respectively, in models of cocaine relapse. Using a model of context-induced relapse, both RO5203648 and RO5256390 dose-dependently suppressed cocaine seeking after a 2-week period of withdrawal from chronic cocaine self-administration. In a model of extinction-reinstatement, RO5203648 completely inhibited cocaine-primed reinstatement of cocaine seeking. At doses that effectively suppressed cocaine seeking neither RO5203648 nor RO5256390 altered responding maintained by a natural reward. Moreover, fast scan cyclic voltammetry data showed that RO5203648 prevented cocaine-induced DA overflow in the nucleus accumbens without altering DA half-life, suggesting that the partial TAAR1 agonist attenuated cocaine-stimulated DA overflow by mechanisms other than direct interference with DA uptake. Collectively, these data provide strong evidence in support of TAAR1 as a neuropharmacological target for the treatment of cocaine addiction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available